Cannabidiol (CBD) for Refractory Epilepsy in Dogs: What the Evidence Shows
Cannabidiol (CBD) has gained attention as a potential supplementary treatment for refractory idiopathic epilepsy in dogs. A recent systematic review examined randomized controlled trials (RCTs) evaluating CBD versus placebo in dogs whose seizures were not controlled with standard therapy.
Only three studies met inclusion criteria. Key observations included:
Efficacy: All studies suggested that CBD treatment may reduce seizure frequency, though results were variable.
Adverse effects: Ataxia was the most commonly reported effect and a reason for withdrawal in some cases. Other effects included vomiting, diarrhea, changes in appetite or behavior, somnolence, and elevated serum alkaline phosphatase (ALP) levels.
Study quality: All three trials had a moderate to high risk of bias, limiting the reliability of the findings.
Takeaway for veterinarians: Current evidence is insufficient to draw definitive conclusions about CBD’s efficacy or safety as an adjunctive treatment for refractory epilepsy in dogs. More high-quality RCTs are needed to clarify the optimal dosing, true clinical benefit, and potential adverse effects.
Read full study here: Cannabidiol treatment for refractory idiopathic epilepsy in dogs: A systematic review with risk of bias assessment
